markets

Windward Bio Debuts on Nasdaq, Shares Surge 68% on IPO Day

Summarized from All Financial Services & Investing

Clinical-stage biotech Windward Bio priced its IPO at $17 per share and closed its first trading day at $28.50 on Nasdaq.

Windward Bio Debuts on Nasdaq, Shares Surge 68% on IPO Day

Windward Bio, a clinical-stage biotechnology company backed by Qiming Venture Partners, made its Nasdaq debut on November 13, 2026, under the ticker symbol WWB, marking a significant milestone for the Shanghai-based immunology firm.

The company priced its initial public offering at $17.00 per share, but investor demand pushed the stock sharply higher on the first day of trading. Shares closed at $28.50, representing a gain of roughly 68 percent from the IPO price — a strong opening performance by any measure in the current biotech capital markets environment.

Read more Leverage Shares Launches 2x Long Anthropic ETF as ANT Debuts on Nasdaq →

Windward Bio operates in the immunology space, a therapeutic area that has drawn sustained investor interest as drugmakers pursue next-generation treatments for autoimmune and inflammatory conditions. The company's listing adds to a pipeline of biotech firms seeking U.S. public market access despite a volatile fundraising climate.

Qiming Venture Partners, one of Asia's prominent venture capital firms with a track record of backing life sciences companies, holds a portfolio stake in Windward Bio. The Nasdaq listing gives the company access to U.S. institutional capital to advance its clinical programs.

Continue reading at All Financial Services & Investing.

Frequently Asked Questions

Q.What was Windward Bio's IPO price on Nasdaq?

Windward Bio priced its IPO at $17.00 per share when it listed on Nasdaq on November 13, 2026.

Q.What is Windward Bio's Nasdaq ticker symbol?

Windward Bio trades on Nasdaq under the ticker symbol WWB.

Q.Who is the venture capital backer behind Windward Bio?

Windward Bio is a portfolio company of Qiming Venture Partners, one of Asia's prominent venture capital firms focused on life sciences and technology.

More in markets →